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1. Introduction  
Recent advances in therapeutic regimens targeting aberrant proliferation of leukemia cells 
have led to a decline in the mortality of patients with acute leukemia. Nevertheless, a 
number of patients still suffer from refractory disease or relapse, indicating that more 
innovative and effective therapeutic strategies are required to achieve superior outcomes. 
One of the major indicators of poor prognosis in leukemia patients is extramedullary 
infiltration or dissemination of leukemia cells. In particular, leukemia cell infiltration into 
the central nervous system is one of the major complications negatively influencing 
prognosis. However, little is known about the mechanisms responsible for extramedullary 
dissemination of leukemia cells compared to those responsible for solid tumor metastasis.  
The chemokine SDF1 (stromal derived factor-1) and its receptor CXCR4 regulate trafficking 
of normal hematopoietic stem cells (HSC) as well as metastasis of solid tumor cells. 
Similarly, the majority of acute myeloid leukemia (AML) cells express CXCR4 and migrate 
in response to SDF1, suggesting that the SDF1/CXCR4 axis may be involved in the 
dissemination of AML cells to various organs. A recent study also suggests that 
chemokine/chemokine receptor interactions orchestrate extramedullary dissemination in 
childhood AML. Moreover, signaling through the chemokine receptor CCR7 is crucial for 
infiltration of T-ALL cells in the central nervous system. Our recent studies indicate that 
internal tandem duplication mutations of the Flt3 gene (ITD-Flt3), found in patients with 
AML, significantly augments migration of hematopoietic cells by deregulating CXCR4 
signaling that are qualitatively distinct from cells lacking ITD-Flt3 and facilitate their 
infiltration to visceral organs while decreasing their homing to the bone marrow. ITD-Flt3 
regulates overlapping as well as functionally distinct signaling pathways down-stream of 
SDF1/CXCR4 compared to cells that do not harbor ITD-Flt3 mutations. The data suggest 
that ITD-Flt3 may facilitate dissemination of leukemia cells by modulating SDF1/CXCR4 
signaling and that blocking this functional cross-talk between ITD-Flt3 and CXCR4 
pathways may have therapeutic benefit. Therefore, genes differentially regulated by SDF1 
specifically in ITD-Flt3 cells may represent key targets regulating aberrant migration by 
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ITD-Flt3 in response to SDF1 to prevent unnecessary dissemination and invasiveness of 
ITD-Flt3+ acute leukemia cells without affecting normal hematopoiesis. This chapter will 
describe gene and receptor signaling pathways responsible for aberrant trafficking of acute 
leukemia cells and discuss therapeutic implications of antagonizing chemokine receptor 
signaling to selectively block extramedullary dissemination of leukemia cells. 
2. Dissemination of acute leukemia and the role of chemokines and 
chemokine receptors 
Despite significant advances in treatments for patients with acute leukemia during the past 
decade, the prognosis of patients with minimal residual disease is generally poor and 
recurrence of the disease is common. One of the major complications that leads to poor 
outcomes of both adults and pediatric patients with acute leukemia is central nervous 
system (CNS) infiltration of leukemia cells. Intensified intrathecal chemotherapy and cranial 
irradiation for prophylaxis of CNS relapse can lead to serious adverse side effects, 
particularly secondary tumors, bone marrow suppression, growth impairment and 
endocrine complications (Pui CH & Howard SC, 2008). In order to minimize the treatment 
associated mortality, blocking leukemia cell invasion and migration may represent a rational 
alternative strategy. However, despite the clinical importance of CNS infiltration of 
leukemia cells, little is known about the underlying mechanism. In addition to CNS, 
leukemia cells are often found in other extramedullary sites, including skin and visceral 
organs, which is also an adverse prognostic factor (Byrd JC et al., 1995, Kaneider NC et al., 
2002). It is conceivable that leukemia stem cells are derived from a single transformed clone 
in the bone marrow that subsequently peripheralize into the peripheral blood circulation 
and home to other organs or different sites within the marrow where they occupy normal 
hematopoietic niches and impair production of functionally normal blood cells. Similar 
processes can take place in simultaneously or successive manner, which in turn causes 
serious hematological complications. Dissemination of AML cells to other marrow sites 
increases the frequency for AML cells to interact with normal marrow niches and 
extracellular matrix (ECM), such as stromal fibronectin, via surface integrins, which is one of 
the mechanisms responsible for minimal residual disease in AML (Matsunaga T et al., 2003). 
Therefore, dissemination of acute leukemia cells must be considered a crucial step in 
leukemic progression (Figure 1). The current chemotherapies and molecular targeting drugs 
were designed to kill leukemia cells but none of them are able to antagonize their movement 
and trafficking. Understanding molecular mechanisms regulating aberrant leukemia cell 
trafficking will aid in developing innovative therapeutic modalities to block leukemic 
infiltration to secondary organs, and will lead to superior outcomes of leukemia treatment. 
One of the major causative molecules associated with AML and poor prognosis is internal 
tandem duplication mutation of the Flt3 kinase gene (ITD-Flt3). Several Flt3 kinase 
inhibitors have been developed and evaluated in early clinical trials with varied degrees of 
success, achieving >50% blast reduction in 12.5 to 81.3% of patients, with the duration of 
response ranging from two weeks to five months (Fiedler W et al., 2003, Smith BD et al., 
2004, Stirewalt DL & Radich JP, 2003), indicating that targeting cell autonomous mechanism 
alone by these therapies was not sufficient to produce a complete cure. In this regard, the 
discovery of the leukemia cell niche identifies a new concept and suggests potential 
therapeutic approaches to antagonize interaction between the leukemia cell and their niche 
in addition to those targeting cell autonomous mechanisms. The leukemia cells destroy the 
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normal hematopoietic niche and create their own niche by down-regulating SDF1 in the 
lesion where leukemia cells invade in the bone marrow (Colmone et al., 2008). 
Extramedullary infiltration of AML to distant organs likely accompanies creation of new 
niches in secondary organs by the leukemia cells, which in turn protects them from various 
chemotherapeutic stimuli.  
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Fig. 1. Dissemination of leukemia cells is a crucial step for disease progression 
Chemokines and their receptors play an important role in trafficking of hematopoietic stem 
cells (HSC) (Lapidot T & Petit I, 2000) and metastasis of tumor cells to distant organs (Muller 
A et al., 2001). The major chemokine regulating homing and mobilization of HSC is stromal 
cell-derived factor-1 alpha (SDF1), a ligand for the cell surface CXCR4 receptor (Lapidot T & 
Petit I, 2000). SDF1 is expressed by osteoblasts, stromal cells and vascular endothelial cells in 
the bone marrow and attracts and retains HSC in the marrow niche (Lane SW, Scadden DT, 
& Gilliland DG, 2009). Within the niche, leukemia cells receive survival cues from 
osteoblasts and endothelial cells in the form of various cytokines and adhesion molecules 
provided by niche cells, which in turn increase their resistance to cytoreductive therapies 
(Lane SW, Scadden DT, & Gilliland DG, 2009). However, in skin, brain and visceral organs, 
extramedullary involvement is occasionally observed in patients with AML and ALL (Byrd 
JC, Edenfield WJ, Shields DJ, & Dawson NA, 1995, Pui CH & Howard SC, 2008). Leukemia 
cells need to leave their original bone marrow niche and find their home in the distant 
secondary niche for initiation of extramedullary dissemination. The mechanism for 
extramedullary infiltration of leukemia cells remains unexplored. Leukemia cells in the 
marrow express higher CXCR4 compared to their circulating counterparts, suggesting that 
interaction between SDF1 and CXCR4 facilitates retention of leukemia cells in the marrow 
niche (Spoo AC et al., 2006). The majority of leukemia cells express CXCR4 and migrate in 
response to SDF1. Antagonizing CXCR4 inhibits engraftment and development of AML in a 
human xenograft human AML model, suggesting that CXCR4 is required for human AML 
to home to marrow niches (Tavor S et al., 2004). Higher CXCR4 expression predicts 
extramedullary infiltration in pediatric patients with ALL (Crazzolara R et al., 2001) and 
functional CXCR4 microparticles and SDF1 correlate with circulating AML (Kalinkovich et 
al., 2006). These data suggest that chemokine signaling pathways are likely to play crucial 
roles in the dissemination of leukemia cells to secondary organs. Recent studies suggest that 
releasing leukemia cells from the marrow niche by blocking SDF1/CXCR4 interaction is 
effective in increasing their sensitivity to cytoreductive treatment (Nervi B et al., 2009). 
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Instead of this strategy that principally targets aberrant leukemia cell proliferation, 
modulating functions of CXCR4 or other chemokine signaling in leukemia cells themselves 
may represent an alternative strategy to reduce their dissemination to secondary organs.  
2.1 Physiological role of SDF1 and CXCR4 
SDF1 is expressed in spleen, liver, lung, kidney, thymus, brain (Nervi B et al., 2009), stromal 
cells (Nagasawa T et al., 1994) and osteoblasts (Jung Y et al., 2006, Semerad CL et al., 2005) in 
bone marrow and regulates development of hematopoietic cells, immune cells, blood 
vessels, heart and brain (Tachibana K et al., 1998, Zou YR et al., 1998). Targeted disruption of 
CXCR4 gene results in impaired bone marrow myelopoiesis and B-lymphopoiesis (Zou YR 
et al., 1998), which is a similar phenotype with SDF -/- mice (Nagasawa T et al., 1996). One 
of the major physiological roles of the SDF1/CXCR4 axis is to regulate homing, retention, 
and survival of primitive hematopoietic stem and progenitor cells (HSPC) (Christopherson 
KW 2nd et al., 2003, Kim CH & Broxmeyer HE, 1998, Levesque JP et al., 2003, Liles WC et al., 
2003, Peled A et al., 1999). Interaction between SDF1 and its receptor CXCR4 is believed to 
play an important role in these processes. SDF1 can attract HSPC that express CXCR4 to the 
marrow microenvironment (Kim CH & Broxmeyer HE, 1998, Peled A et al., 1999), while 
disruption of SDF1/CXCR4 interaction within marrow can under appropriate circumstances 
facilitate their mobilization to the peripheral circulation (Liles WC et al., 2003)(Figure 2).  
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Fig. 2. SDF1 and CXCR4 regulate homing and mobilization of hematopoietic stem cells 
HSCs can be found in contact with the cells expressing high amounts of SDF1 (Sugiyama T 
et al., 2006). SDF1/CXCR4 signaling plays an essential role in maintaining the quiescent HSC 
pool (Sugiyama T et al., 2006). SDF1 can activate adhesion molecules, particularly very late 
antigen-4 (VLA-4) and lymphocyte function associated antigen-1 (LFA-1) on HSPC, which 
also regulate the homing process (Peled A et al., 2000). SDF1 enhances survival or 
proliferation of normal hematopoietic progenitor cells (Broxmeyer HE et al., 2003) and 
regulates development of B-cells (Ma Q et al., 1999). Expression of CXCR4 is up-regulated by 
various cytokines, including stem cell factor (Peled A et al., 1999), VEGF, bFGF, EGF, IL2, 
IL4, IL6, IL7, IL10 and IL15 (Busillo JM & Benovic JL, 2007). In contrast, Flt3 ligand (Fukuda 
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S et al., 2005), TNF and INF down-regulate CXCR4 expression (Busillo JM & Benovic JL, 
2007). Adrenergic inputs down-regulate SDF1 in the marrow environment during daytime 
(Mendez-Ferrer et al., 2008), but up-regulate CXCR4 on HSC at night (Lucas D et al., 2008). 
Although it was believed that CXCR4 was the only receptor for SDF1, a recent study 
identified CXCR7 as a secondary receptor for SDF1 (Balabanian K et al., 2005). However, 
unlike CXCR4, CXCR7 mediates only cell survival, clustering and proliferation and lacks the 
ability to mediate chemotaxis (Burns JM et al., 2006).  
2.2 SDF1/CXCR4 in hematological malignancies  
CXCR4 is expressed in most hematological malignancies including chronic lymphocytic 
leukemia (CLL), chronic myeloid leukemia (CML) (Burger JA et al., 1999), acute 
lymphoblastic leukemia (ALL) (Bradstock KF et al., 2000, Mohle R et al., 2000), acute myeloid 
leukemia (AML) (Kalinkovich A et al., 2006, Rombouts EJ et al., 2004) (Voermans C et al., 
2002), B-cell lymphoma (Burger JA et al., 1999, Trentin L et al., 2004), T-cell non Hodgkin 
lymphoma (NHL) (Weng AP et al., 2003) and multiple myeloma (Weng AP et al., 2003). High 
expression of CXCR4 predicts extramedullary organ infiltration in childhood ALL 
(Crazzolara R et al., 2001) and elevated CXCR4 expression is associated with poor prognosis 
of patients with AML (Rombouts EJ et al., 2004, Spoo AC et al., 2006). Extramedullary 
infiltration of M5 AML is associated with high CXCR4 expression (Mohle R et al., 2000), 
suggesting that the SDF1/CXCR4 axis may be involved in the extramedullary disease of 
AML. In contrast, a recent report suggests that involvement of CXCR4 in skin infiltration of 
AML is unlikely (Faaij CMJM et al., 2010). The extramedullary dissemination of AML may 
be associated with differentiation of AML that appears to affect CXCR4 expression, namely 
lower CXCR4 in undifferentiated M0, M1 and M2 compared to more differentiated M3, M4 
and M5. Another study described that extramedullary dissemination of AML depends on 
single nucleotide polymorphism (SNP) of SDF1 (Dommange F et al., 2006). Furthermore, 
SDF1 can recruit endothelial progenitor cells to the tumor microenvironment to facilitate 
neo-vascularization (Orimo A et al., 2005), which may be required for continued growth of 
leukemia cells in the extramedullary niche. It has been suggested that targeting CXCR4 
signaling pathways may be an important therapeutic strategy for ALL (Juarez J et al., 2003), 
CLL (Burger M et al., 2005a) and NHL (Bertolini F et al., 2002). Recent data indicates that 
SDF1 plays an important role in protecting AML cells in the marrow niche, especially 
during intensive chemotherapy (Zeng ZH et al., 2009). Blocking SDF1/CXCR4 signaling 
releases leukemia cells from marrow niches into blood circulation, dissociating them from 
the protective signal in the niche, and increases their sensitivity to chemotherapy (Nervi B et 
al., 2009). Physiological circadian oscillation of SDF1 in the marrow niche and CXCR4 
expression on HSC allows HSC to peripheralize into the blood circulation (Lucas D et al., 
2008, Mendez-Ferrer S et al., 2008). It is likely that similar fluctuation in SDF1 and CXCR4 on 
leukemia stem cells that can affect their mobilization and homing may exist.  
Similarly, recent evidence suggests that SDF1/CXCR4 signaling plays a central role in 
metastasis of solid tumors to the bone marrow or other tissues where SDF1 is expressed 
(Geminder H et al., 2001, Muller A et al., 2001) and serves as a survival factor for various 
solid tumor or leukemia cells (Burger JA et al., 2000, Orimo A et al., 2005, Zhou Y et al., 2002). 
A growing body of evidence indicates that SDF1/CXCR4 signaling and oncogenic proteins, 
such as BCR/ABL in CML (Geay JF et al., 2005, Mishra S et al., 2006, Ptasznik A et al., 2002, 
Salgia R et al., 1999), HER2 in breast cancer (Cabioglu N et al., 2006, Li YM et al., 2004) and 
Internal Tandem Duplication (ITD)-Flt3 in AML (Fukuda S et al., 2005, Fukuda S & Pelus 
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LM, 2006), functionally interact to modulate migration of malignant cells. Their concomitant 
expression with CXCR4 is often associated with poor patient prognosis (Li YM et al., 2004, 
Mishra S et al., 2006).  
2.3 Hematopoietic growth factors that affect SDF1/CXCR4 signaling and migration of 
leukemia cells 
While hematopoietic growth factors normally stimulate proliferation and survival of HSPC, 
some of them can stimulate migration. Stem cell factor (SCF) and Flt3 ligand (FL) are the 
respective ligands for the receptor tyrosine kinases c-kit and Flt3 that are expressed on 
HSPC. Although they have similar but distinct roles in HSPC proliferation and survival 
(Lyman SD & Jacobsen SEW, 1998), they both stimulate migration of human cord blood 
(UCB) CD34+ cells (Fukuda S et al., 2005, Kim CH & Broxmeyer HE, 1998). In contrast to the 
chemotactic activity of SDF1 that stimulates directional cell migration towards the 
chemokine (chemotaxis), SCF and FL stimulate random cell migration (chemokinesis). SCF 
increases SDF1-induced chemotaxis of the AML line MO7e cells when combined with SDF1 
(Kim CH & Broxmeyer HE, 1998). Similarly, FL enhances migration of the RS4;11 bi-
phenotypic acute leukemia cell lines to SDF1 (Fukuda S et al., 2005). These data suggest that 
hematopoietic growth factors regulate migration of acute leukemia cells by modulating the 
SDF1/CXCR4 axis.  
Although both SCF as well as FL enhance migration of human UCB CD34+ cells induced by 
SDF1 in a similar manner, prolonged exposure the cells to SDF1 result in differential 
migratory responses. Prolonged incubation of UCB CD34+ cells with SCF up-regulates 
CXCR4 expression and enhances subsequent migration to SDF1 (Peled A et al., 1999). In 
contrast, incubation of UCB CD34+ cells with FL over 24 hrs down-regulates CXCR4 
expression coincident with a decrease in subsequent migration to SDF1 (Fukuda S et al., 
2005). Down-regulation of CXCR4 by incubation with FL is consistent with reduction of 
CXCR4 in CD34+ cells transfected with ITD-Flt3 that activate Flt3 without ligand binding 
(Jacobi A et al., 2010). Similar to human CD34+ cells, the differential migration to SDF1 
modulated by FL was also observed in Ba/F3 cells expressing human wild-type Flt3 
receptor. The synergistic cell migration in response to the combination of SDF1 and FL was 
associated with synergistic phosphorylation of ERK, Akt and CREB. These results suggest 
that ERK, Akt and CREB are involved in the synergistic increase in migration by the 
combination of SDF1 plus FL. On the other hand, pre-incubation of Ba/F3 cells expressing 
Flt3 with FL for 24 hours down-regulates CXCR4 and significantly diminishes their 
subsequent migration to SDF1 compared to control cells pre-incubated without FL. In 
contrast to synergistic response, phosphorylation of ERK, Akt and CREB in response to 
SDF1 was reduced in the cells pretreated with FL compared to untreated control cells, 
further validating the differential modulation of SDF1/CXCR4 signaling by FL/Flt3 
(Fukuda S et al., 2005). Down-regulation of CXCR4 by FL may explain one of the 
mechanisms of HPC mobilization by FL administration (Brasel K et al., 1997). A similar 
effect by SCF is not known. These data indicate overlapping but distinct roles of c-kit and 
Flt3 signaling on CD34+ cell migration induced by SDF1. 
2.4 Bcr/abl alters signaling and chemotactic response mediated by SDF1/CXCR4 
Chronic myeloid leukemia (CML) is caused by the Bcr/Abl oncogene with constitutive 
kinase activity, a result of a reciprocal translocation between chromosmes 9 and 22 
(Kurzrock R et al., 1988, Sawyers CL, 1999). Bcr/abl is occasionally observed in acute 
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lymphoblastic leukemia cells (ALL) as well (Mishra S et al., 2006). One of the characteristics 
of CML is an early release of myeloid cells from the marrow and their accumulation in the 
blood and spleen, suggesting that cell retention in the marrow or migration may be 
impaired. CML cells show reduced adhesion to stromal cells and extracellular matrix 
(Gordon MY et al., 1987, Verfaillie CM et al., 1992) that may concomitantly contribute to 
impaired retention. Ectopic Bcr/Abl increases spontaneous motility of hematopoietic cell 
lines; however, it significantly reduces chemotactic response to SDF1 (Salgia R et al.,1999). 
Homing of mouse hematopoietic Ba/F3 cells expressing Bcr/Abl to spleens in the mice that 
have been ectopically injected with SDF1 was significantly reduced compared to control 
cells, although their homing to the bone marrow, lung or blood was not affected. The 
migratory response of primary CML cells to SDF1 at blast crisis was profoundly reduced, 
which was associated with reduced CXCR4 expression, while CD34+ cells at chronic phase 
migrate normally in response to SDF1 (Geay JF et al., 2005). In addition, higher Bcr/abl 
expression induces a marked down regulation of CXCR4, while treatment with STI-571 
(Imatinib), the Bcr/abl antagonist, that blocks Bcr/abl activity restores CXCR4 expression in 
CD34+ cells from patients in blast crisis (Geay JF et al.,2005). The reduction in CXCR4 
expression and loss of response to SDF1 mediated by Bcr/abl may allow CML cells to exit 
bone marrow, resulting in infiltration to secondary organs, including blood and spleen. 
These data suggest that Bcr/abl regulates trafficking of hematopoietic cells by modulating 
SDF1/CXCR4 function, which is associated with disease progression and extramedullary 
dissemination. Conversely, SDF1 can increase resistance of acute lymphoblastic leukemia 
cells expressing Bcr/abl to STI-571, suggesting that SDF1/CXCR4 signaling may augment 
Bcr/abl signaling that enhances resistance to the therapy (Mishra S et al., 2006).  
2.5 ITD-Flt3 alters chemotaxis induced by SDF1/CXCR4 signaling 
Genetic mutations (Internal tandem duplication: ITD) of the Flt3 gene that pathologically 
auto-activate Flt3 tyrosine kinase activity have been found in ~25-30% of patients with AML 
and elevated CXCR4 receptor expression is associated with poor outcome in patients with 
acute myeloid leukemia (AML) (Levis M & Small D, 2003, Spoo AC et al., 2006), suggesting 
a role for ITD-Flt3 and CXCR4 in disease progression. Fifteen percent of patients with 
extramedullary AML were positive for ITD-Flt3 (Ansari-Lari et al., 2004), suggesting that 
ITD-Flt3 may affect migration and trafficking of leukemia cells. ITD-Flt3 mutations cause 
extramedullary infiltration of hematopoietic cells with splenomegaly in a myeloproliferative 
disease model in mice (Kelly LM et al., 2002). Consistent with this finding, ITD-Flt3 
significantly increases accumulation of Ba/F3 cells in the spleen shortly after transplantation 
compared to wild-type Flt3 (Fukuda S & Pelus LM, 2006). Stable expression of ITD-Flt3 in 
mouse Ba/F3 and 32D cells significantly increases migration to SDF1 in addition to 
enhancing spontaneous motility (Figure 3) (Fukuda S et al., 2005). This is in contrast to 
Bcr/abl that increases spontaneous motility while reducing migration in response to SDF1 
(Geay JF et al., 2005, Salgia R et al., 1999). Importantly, CXCR4 expression on Ba/F3 cells 
harboring ITD-Flt3 mutations was significantly reduced, indicating that enhanced migration 
is not explained by CXCR4 expression (Fukuda S et al., 2005) (Figure 3). This is consistent 
with down-regulation of CXCR4 in Ba/F3 cells expressing wild–type Flt3 or UCB CD34+ 
cells incubated with FL for over 24 hours. However, longer exposure to FL reduces 
migration to SDF1 (Fukuda S et al., 2005). In contrast to synergistic phosphorylation of ERK, 
Akt or CREB coincident with enhanced migration to SDF1 and FL in Ba/F3 cells harboring 
wild-type Flt3, accentuated migration to SDF1 by ITD-Flt3 was not associated with an 
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increase in phosphorylation of these molecules (Table 1). These findings suggest qualitative 
differences between ITD-Flt3 signaling and FL /wild type Flt3 signaling, even if both stimuli 
result in similar enhancement in migration to SDF1.  
 
FL prolonged stimulation with FL ITD-Flt3
CXCR4 no change } decrease ‾ decrease ‾
Migration to SDF1 increase | decrease ‾ increase |
Phospho ERK, Akt, CREB increase | decrease ‾ no change }
 
Table 1. Differential regulation on CXCR4 expression and migration to SDF1 by FL/wild-
type Flt3 signaling or ITD-Flt3 in Ba/F3 cells 
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Fig. 3. Migration and CXCR4 expression of ITD-Flt3 + or ITD-Flt3 - Ba/F3 cells. Migration of 
ITD-Flt3+ cells towards SDF1 was significantly elevated compared to ITD-Flt3 – cells  
(* P<0.05: left panel). However, CXCR4 expression was significantly reduced in 
ITD-Flt3 + cells compared to ITD-Flt3 – cells (right panel), suggesting that the enhanced 
migration is not a quantitative increase of CXCR4 signaling but more likely to be a 
qualitative alteration of CXCR4 signaling by ITD-Flt3. 
Enhanced chemotactic response to SDF1 is partially mediated through Ras signaling, since 
dominant negative H-Ras dramatically inhibits spontaneous and SDF-mediated migration 
of Ba/F3 cells, while constitutively active H-Ras expression in Ba/F3 cells harboring wild-
type Flt3 increases chemotactic response to SDF1 to a similar extent as ITD-Flt3 (Fukuda S & 
Pelus LM, 2006). Accentuated migration of Ba/F3 cells to SDF1 induced by ITD-Flt3 was 
barely inhibited by the Flt3 inhibitor AG1296 or the CXCR4 antagonist AMD3100 alone, 
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whereas it was partially inhibited by the combination of both compounds (Figure 4). 
Surprisingly, ITD-Flt3 mutations also increase cell migration away from an SDF1 gradient 
compared to control cells (Fukuda S et al., 2005). This result implies that ITD-Flt3 may 
facilitate peripheralization of leukemia cells out of the bone marrow niche where SDF1 is 
present, in addition to the effects of enhancing cell homing towards SDF1 in the niche. 
 
10 20 30 40 50 60
SDF1
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wild-type Flt3
ITD Flt3
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%migration
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Fig. 4. Migration of Ba/F3 cells expressing ITD-Flt3 pretreated with AMD3100 and/or 
AG1296 
In contrast to the mouse cell system where human ITD-Flt3 mutations were retrovirally 
transduced into Ba/F3 cells and 32D cells (Fukuda S et al., 2005), a recent report has shown 
that transient expression of ITD-Flt3 in human CD34+ cells inhibited migration to SDF1 
concomitant with reduction in cell surface CXCR4 expression (Jacobi A et al., 2010). While 
reduction in CXCR4 in CD34+ cells by ITD-Flt3 is consistent with Ba/F3 cells transduced 
with ITD-Flt3, the differential effects on migration to SDF1 by these cells may reflect the 
timeframe of exposure to SDF1 following introduction of ITD-Flt3 into the cells. Shortly 
after introduction of ITD-Flt3, expression of CXCR4 is down-regulated, thereby inhibited 
migration to SDF1. In contrast, prolonged expression of ITD-Flt3 leads to functional 
activation of CXCR4 signaling pathways and increases cell migration, while maintaining 
lower CXCR4 expression, suggesting that ITD-Flt3 may differentially regulate chemotactic 
response to SDF1. These findings suggest that migration of leukemia cells to SDF1 may be 
diminished shortly after emergence of ITD-Flt3 in the patients due to reduction of CXCR4 
level and concomitant quantitative decline in CXCR4 signaling. This does not accompany 
qualitative changes in CXCR4 signaling. In contrast, their migration to SDF1 is enhanced at a 
later stage of the disease long after ITD-Flt3 appearance, most likely due to subsequent 
functional alteration of CXCR4 signaling by ITD-Flt3 that is not coupled with CXCR4 
expression level. Reduced migration to SDF1 by ITD-Flt3 can facilitate their 
peripheralization into blood at an early stage of the disease whereas enhanced migration 
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to SDF1 may aid to increase homing of the leukemia cells to the organs where SDF1 is 
expressed at a later stage of the disease.  
2.6 Identification of CXCR4 pathways that are selectively regulated by ITD-Flt3 
CXCR4 is expressed in the majority of hematopoietic cells, including HSC, T-cells, B-cells 
and myeloid cells. While antagonizing CXCR4 has been shown to be a safe way to collect 
HSC from the healthy donors (Liles WC et al., 2003), it is known that SDF1/CXCR4 signaling 
provides survival effects to the primitive hematopoietic cell compartment (Broxmeyer HE et 
al., 2003), therefore the long term effect of CXCR4 antagonist on normal hematopoietic cell 
function should be monitored with caution. In this regard, concomitant use of a CXCR4 
antagonist with chemotherapeutic drugs may enhance toxicity, not just to leukemia cells, 
but also to normal HSC. In order to minimize toxicity on HSC by CXCR4 antagonist, it 
would be necessary to identify selective signaling molecules downstream of CXCR4 that are 
specifically regulated in leukemia stem cells but not in normal HSC. Similarly, identification 
of selective CXCR4 related molecular pathways regulating homing of leukemia cells distinct 
from normal hematopoietic cells will aid to antagonize aberrant trafficking of leukemia cells 
without affecting normal hematopoiesis.  
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Fig. 5. Functional classification of genes downstream of SDF1/CXCR4 in ITD-Flt3 + versus 
ITD-Flt3 - mouse Ba/F3 cells. 
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As we previously described, ITD-Flt3 mutations enhance migration of hematopoietic cells to 
the chemokine SDF1 (Figure 3) (Fukuda S et al., 2005), suggesting that ITD-Flt3 may facilitate 
dissemination of leukemia cells by modulating the SDF1/CXCR4 signaling pathway. The 
enhanced migration to SDF1 by ITD-Flt3 positive cells was associated with down regulation 
of CXCR4 compared to control cells lacking ITD-Flt3. This suggests that the enhanced 
migration to SDF1 by ITD-Flt3 is not a consequence of a quantitative increase in 
SDF1/CXCR4 signaling, which led us to investigate qualitative alteration of CXCR4 
signaling by ITD-Flt3. Analysis of gene expression in ITD-Flt3- and ITD-Flt3+ Ba/F3 cells 
migrating to SDF1 indicated that SDF1 modulates 4.0% of 40,000 genes analyzed in ITD-
Flt3+ cells, of which 2.5% were regulated by SDF1 exclusively in ITD- Flt3+ cells. Figure 4 
indicates comparison of changes in gene expression before and after migration to SDF1 
(SDF1 responsive genes) between ITD-Flt3- and ITD-Flt3+ Ba/F3 cells. Genes modulated in 
ITD-Flt3- cells or ITD-Flt3+ cells following migration to SDF1 compared to these cells 
analyzed before migration were functionally classified based on Gene Ontology Term using 
DAVID software (Huang DW et al., 2009)(Figure 5). X-axis represents functional categories 
of the individual genes analyzed in the Y-axis. Functional classification indicated that 
several functional signaling pathways were significantly enriched exclusively in ITD-Flt3 
but not in control cells. These data indicate that enhanced cell migration to SDF1 induced by 
ITD-Flt3 is likely mediated through activation of selective CXCR4 signaling pathways that 
are functionally distinct from ITD-Flt3- cells and that are not coupled with CXCR4 
expression. Importantly, several of these CXCR4 downstream molecules selectively 
regulated by ITD-Flt3 are products of genes known to be deregulated in AML stem cells 
(Majeti R et al., 2009). Leukemia stem cells (LSC) are likely responsible for dissemination to 
secondary organs in addition to disease initiation and recurrence. Genes deregulated by LSC 
and regulated by SDF1 specifically in ITD-Flt3+ cells may represent key targets to prevent 
unnecessary dissemination and invasion of ITD-Flt3+ acute leukemia cells without affecting 
normal hematopoiesis. In addition to the genes selectively regulated by SDF1 in ITD-Flt3+ 
cells, approximately 30 mRNAs that are known to be functionally associated with cell 
motility or migration were deregulated in ITD-Flt3+ cells compared to ITD-Flt3- cells. This 
data suggests that ITD-Flt3 itself may affect cell migration. This is consistent with enhanced 
spontaneous migration by ITD-Flt3 in Ba/F3 cells (Fukuda S et al., 2005). 
Our working hypothesis on ITD-Flt3+ AML cell trafficking regulated by interaction between 
ITD-Flt3 and SDF1/CXCR4 pathway is shown in Figure 6. The presence of ITD-Flt3 
mutations decrease CXCR4 expression, thereby reducing interaction between SDF1 and 
AML cells and allowing their release from bone marrow. In addition, ITD-Flt3+ cells can 
migrate away from SDF1 more efficiently compared to ITD-Flt3- cells, which can also 
contribute to their peripheralization/egress. Alternatively, migration to SDF1 may not be 
enhanced shortly after ITD-Flt3 emergence or at an early stage of the disease owing to the 
reduction of CXCR4 that without activation of CXCR4 signaling. Prolonged exposure to 
aberrant signaling generated by ITD-Flt3 functionally activates SDF1/CXCR4 signaling in 
the ITD-Flt3+ cells that is different from ITD-Flt3- cells (Figure 5) while maintaining lower 
levels of CXCR4 expression (Figure 3). This suggests that enhanced migration to SDF1 is a 
consequence of functional alteration of CXCR4 signaling rather than CXCR4 up-regulation. 
This will help AML cells to home to the distant organs or secondary bone marrow where 
SDF1 is present. Circadian oscillation of SDF1 in the marrow niche and CXCR4 expression 
on HSC (Lucas D et al., et al 2008, Mendez-Ferrer S et al., 2008) may also exist in the 
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leukemia niche and leukemia stem cells expressing ITD-Flt3. This fluctuation of SDF1 and 
CXCR4 can also affect their mobilization and homing. De-sensitization of CXCR4 signaling 
following exposure to SDF1 may also be distinct in leukemia cells versus normal HSC, 
which can affect their response to SDF1.  
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Fig. 6. Suggested model for ITD-Flt3+ AML cell trafficking regulated by interaction between 
ITD-Flt3 and SDF1/CXCR4 pathway 
2.7 Role of other chemokines and their receptors for leukemia cell dissemination 
Childhood T-ALL often relapses in the CNS (Pui CH & Howard SC, 2008). Oncogenic 
Notch1 signaling that is frequently activated in T-ALL regulates CCR7 expression. CCL19 
expressed in central nervous system serves as a chemo-attractant for T-ALL cells with 
elevated expression of CCR7. Antagonizing CCR7 and its chemokine ligand CCL19 inhibit 
CNS infiltration of T-ALL in an animal model (Buonamici S et al., 2009). On the other hand, 
overexpression of CCR7 was sufficient to recruit T-ALL cells into the CNS. The data 
indicates that CCL19/CCR7 signaling activated by oncogenic Notch1 regulates CNS 
infiltration of T-ALL and that targeting the CCR7 pathway may represent a novel 
therapeutic strategy for treatment of CNS prophylaxis of T-ALL (Buonamici S et al., 2009) 
(Figure 7). 
While antagonizing CCR7 signaling is a promising strategy to block invasion of T-ALL cells, 
it may impair immune surveillance by normal T-cells, since CCR7 is one of the chemokine 
receptors required for T-cell trafficking (Burger M et al., 2005b). Unnecessary immune 
impairment that can cause serious life threatening infection by pathogens needs to be 
avoided during the intensified treatment for leukemia. In this regard, identification of 
selective signaling molecules in the CCR7 pathway in T-ALL that are functionally distinct 
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from normal T-cells is important in order to develop selective strategy with minimal toxicity 
on T-cells.   
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Fig. 7. Migration and invasion of T-ALL cells into central nervous system mediated through 
CCL19/CCR7 pathway 
Mixed lineage leukemia (MLL) frequently found in infant ALL is caused by a chromosomal 
translocation that involves 11q23 (Pieters R, 2009). This is associated with poor outcome 
with relatively high frequency of central nervous involvement compared to older children, 
suggesting that MLL gene rearrangement modulates leukemia cell dissemination. A recent 
report indicates that MEF2C regulates homing and invasiveness of MLL/ENL leukemia 
cells without affecting establishment and maintenance of leukemia stem cells (Schwieger M 
et al., 2009). MEF2 regulates expression of the chemokine receptors CXCR4, CCR2 and CCR5 
and chemokines, such as CCL2, CCL3, CCL4 and CCL6 (Schwieger M et al., 2009). This 
suggests that MLL gene rearrangement regulates homing and invasion of leukemia cells 
through MEF2C by affecting expression of chemokines and their receptors.  
Chemokine receptor expression is differentially regulated in AML patients with skin 
involvement. Skin residing AML cells displayed a different set of chemokine receptors in 
situ, for instance: CCR5, CXCR4, CXCR7 and CX3CR1. However, a recent report indicates a 
high percentage of circulating CCR2 pos AML cells were only detected in patients with 
extramedullary disease (Faaij CMJM et al., 2010). High expression of CCR2 was not observed 
in bone marrow blasts. This study showed that there was no difference in the expression of 
CXCR4, suggesting that CCR2 may be a dominant regulator for skin dissemination of AML.  
3. Conclusion 
Given that various oncogenic molecules responsible for hematological malignancies such as 
ITD-Flt3, Bcr-abl and Ras, modulate response to SDF1, these oncogenes likely modulate 
trafficking of leukemia cells. Although there is no definitive evidence that CXCR4 is indeed 
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involved in the dissemination of acute leukemia, multiple data support that this is most 
likely the case. Blocking CXCR4 appears to be a promising strategy to sensitize leukemia 
cells to chemotherapy by releasing/mobilizing them into the peripheral blood circulation. 
Targeting CXCR4 signaling pathways may also be useful to minimize leukemia cell 
dissemination in addition to sensitizing them to chemotherapy by releasing them from 
marrow niches. This idea is consistent with targeting the CCR7 receptor in T-ALL that 
blocks their CNS dissemination (Buonamici S et al., 2009). Although promising, precautions 
need to be taken since antagonizing CXCR4 initiates mobilization of leukemia cells into 
circulation, which may facilitate secondary organ infiltration. 
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